Home/Filings/4/0001493152-25-028759
4//SEC Filing

Margrave David R. 4

Accession 0001493152-25-028759

CIK 0001763950other

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 4:05 PM ET

Size

5.5 KB

Accession

0001493152-25-028759

Insider Transaction Report

Form 4
Period: 2025-12-18
Margrave David R.
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-12-18+20,00020,000 total
    Exercise: $3.24Exp: 2035-12-17Common Stock (20,000 underlying)
Footnotes (1)
  • [F1]The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.

Documents

1 file

Issuer

Lantern Pharma Inc.

CIK 0001763950

Entity typeother

Related Parties

1
  • filerCIK 0001813162

Filing Metadata

Form type
4
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:05 PM ET
Size
5.5 KB